MDNA — Medicenna Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- CA$151.49m
- CA$134.51m
Annual balance sheet for Medicenna Therapeutics, fiscal year end - March 31st, CAD millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 37.7 | 40.4 | 20.5 | 33.6 | 17 |
| Net Total Receivables | 0.058 | 0.41 | 1.31 | 0.855 | 1.16 |
| Prepaid Expenses | |||||
| Total Current Assets | 37.9 | 42.1 | 23.4 | 36.4 | 19.1 |
| Net Property, Plant And Equipment | 0.068 | 0.032 | 0 | — | — |
| Net Intangible Assets | |||||
| Total Assets | 38 | 42.3 | 23.5 | 36.4 | 19.1 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Current Liabilities | 1.82 | 4.11 | 2.62 | 3.8 | 2.86 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 1.85 | 4.11 | 2.62 | 6.96 | 13.9 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 36.1 | 38.1 | 20.8 | 29.5 | 5.19 |
| Total Liabilities & Shareholders' Equity | 38 | 42.3 | 23.5 | 36.4 | 19.1 |
| Total Common Shares Outstanding |